Optimal monitoring of CML treatment: Molecular and mutation analysis

David Yeung, Susan Branford

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

With successful tyrosine kinase inhibitor treatment, the vast majority of chronic myeloid leukaemia patients diagnosed in chronic phase achieve long-term leukaemia-free survival as well as deep molecular responses. Accurate assessment of residual disease by RT-qPCR not only allows patients at risk of treatment failure to be segregated for treatment intensification but also identify patients with deep molecular responses for treatment cessation studies in the future. Specificity, sensitivity and accuracy of the RT-qPCR assay depend on optimised methodology and high-quality specimens with minimal RNA degradation. International standardisation projects allow for RT-qPCR results to be compared across laboratories and in clinical studies. For patients who fail to achieve a desired treatment outcome, mutational analysis allows for optimised selection of subsequent line therapies.

LanguageEnglish
Title of host publicationMolecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
PublisherSpringer Japan
Pages101-129
Number of pages29
ISBN (Electronic)9784431557142
ISBN (Print)9784431557135
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Keywords

  • BCR-ABL1 RT-qPCR
  • BCR-ABL1 mutation analysis
  • Molecular response

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Yeung, D., & Branford, S. (2015). Optimal monitoring of CML treatment: Molecular and mutation analysis. In Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia (pp. 101-129). Springer Japan. https://doi.org/10.1007/978-4-431-55714-2_7